Regulatory & Compliance
Supreme Court weighing arguments in breast cancer genes case
High stakes for research and medical testing as lawsuit dating back to 2009 opens at the US court of last resort...  »
UK to introduce criminal penalties for design infringement
Brand new measures to enhance the protection of intangible assets are pleasing to the eye for product stylists...  »
Software to crack quality code at EPO and beyond
Technology is on the rise at the European Patent Office – and principal director Ciarán McGinley is excited about the benefits it will bring to the organisation’s stakeholders, writes Matt Packer...  »
Leveraging an edge on the America Invents Act
NewLegal Review explores how IP management technology gives IP owners the flexibility they need to adapt to legislative changes...  »
General counsel emerging at strategic heart of corporations
A KPMG report has found that in-house lawyers are enjoying higher boardroom visibility – particularly in IP-rich organisations, writes Jo Russell...  »
Tipping point arrives for America Invents Act
Paradigm shift in US patent system ready to take effect, bringing fundamental change to the filing process as well as the fee structure, writes Matt Packer...  »
Watershed for ABS firms as BT dials in
Telecoms operator wins licence to provide full litigation support for motoring claims, under new legal services brand BT Law...  »
Asia IP focus – Part Four: Japan
Watertight paperwork and a firm understanding of subtly different licensing types are key to doing business in this important location, writes Michiru Takahashi of Jones Day...  »
Asia IP focus – Part Three: Taiwan (Republic of China/ROC)
Getting evidence right first time at the IP Court and grasping new rules on infringement damages would benefit an overseas entrant to the Republic of China (ROC), writes Po-Chien Chen of Jones Day...  »
Asia IP focus – Part Two: Hong Kong
This bustling Chinese territory is a haven for foreign businesses – but it also attracts risks from mainland-linked shadow companies and the trade in bogus drugs, writes Anita Leung of Jones Day...  »